These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33459229)

  • 61. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.
    Engel T; Hernández F; Avila J; Lucas JJ
    J Neurosci; 2006 May; 26(19):5083-90. PubMed ID: 16687499
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease.
    Ferrer I; Barrachina M; Tolnay M; Rey MJ; Vidal N; Carmona M; Blanco R; Puig B
    Brain Pathol; 2003 Jan; 13(1):62-78. PubMed ID: 12580546
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Roles of glycogen synthase kinase 3 in Alzheimer's disease.
    Cai Z; Zhao Y; Zhao B
    Curr Alzheimer Res; 2012 Sep; 9(7):864-79. PubMed ID: 22272620
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neurofibrillary tangles and tau phosphorylation.
    Brion JP; Anderton BH; Authelet M; Dayanandan R; Leroy K; Lovestone S; Octave JN; Pradier L; Touchet N; Tremp G
    Biochem Soc Symp; 2001; (67):81-8. PubMed ID: 11447842
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors.
    Voigt B; Krug M; Schächtele C; Totzke F; Hilgeroth A
    ChemMedChem; 2008 Jan; 3(1):120-6. PubMed ID: 18000938
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.
    Duka T; Duka V; Joyce JN; Sidhu A
    FASEB J; 2009 Sep; 23(9):2820-30. PubMed ID: 19369384
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
    Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A
    Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells.
    Greco SJ; Sarkar S; Casadesus G; Zhu X; Smith MA; Ashford JW; Johnston JM; Tezapsidis N
    Neurosci Lett; 2009 May; 455(3):191-4. PubMed ID: 19429119
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice.
    Uno Y; Iwashita H; Tsukamoto T; Uchiyama N; Kawamoto T; Kori M; Nakanishi A
    Brain Res; 2009 Nov; 1296():148-63. PubMed ID: 19698704
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease.
    Hernández F; Pérez M; Lucas JJ; Mata AM; Bhat R; Avila J
    J Biol Chem; 2004 Jan; 279(5):3801-6. PubMed ID: 14602710
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.
    Lahmy V; Meunier J; Malmström S; Naert G; Givalois L; Kim SH; Villard V; Vamvakides A; Maurice T
    Neuropsychopharmacology; 2013 Aug; 38(9):1706-23. PubMed ID: 23493042
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Therapeutic implications of glycogen synthase kinase-3β in Alzheimer's disease: a novel therapeutic target.
    Mandlik DS; Mandlik SK; S A
    Int J Neurosci; 2024 Jun; 134(6):603-619. PubMed ID: 36178363
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.
    Duka V; Lee JH; Credle J; Wills J; Oaks A; Smolinsky C; Shah K; Mash DC; Masliah E; Sidhu A
    PLoS One; 2013; 8(9):e75025. PubMed ID: 24073234
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Protein kinase FA/GSK-3 phosphorylates tau on Ser235-Pro and Ser404-Pro that are abnormally phosphorylated in Alzheimer's disease brain.
    Yang SD; Song JS; Yu JS; Shiah SG
    J Neurochem; 1993 Nov; 61(5):1742-7. PubMed ID: 8228990
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tau therapeutic strategies for the treatment of Alzheimer's disease.
    Churcher I
    Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's disease.
    Papasozomenos SCh; Shanavas A
    Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1140-5. PubMed ID: 11805297
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease.
    Fukunaga K; Sakai D; Watanabe K; Nakayama K; Kohara T; Tanaka H; Sunada S; Nabeno M; Okamoto M; Saito K; Eguchi J; Mori A; Tanaka S; Inazawa K; Horikawa T
    Bioorg Med Chem Lett; 2015 Mar; 25(5):1086-91. PubMed ID: 25655721
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.
    Caccamo A; Oddo S; Tran LX; LaFerla FM
    Am J Pathol; 2007 May; 170(5):1669-75. PubMed ID: 17456772
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dehydroevodiamine attenuates tau hyperphosphorylation and spatial memory deficit induced by activation of glycogen synthase kinase-3 in rats.
    Peng JH; Zhang CE; Wei W; Hong XP; Pan XP; Wang JZ
    Neuropharmacology; 2007 Jun; 52(7):1521-7. PubMed ID: 17434540
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
    Leroy K; Yilmaz Z; Brion JP
    Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.